Cargando…

Circulating exosomal immuno-oncological checkpoints and cytokines are potential biomarkers to monitor tumor response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients

Immune checkpoint inhibitors (ICIs) including anti-PD-1 and anti-PD-L1 antibodies, have significantly changed the treatment outcomes of NSCLC patients with better overall survival. However, 15-40% of the patients still fail to respond to ICIs therapy. Identification of biomarkers associated with res...

Descripción completa

Detalles Bibliográficos
Autores principales:	Akbar, Shayista, Raza, Afsheen, Mohsin, Reyad, Kanbour, Aladdin, Qadri, Shahnaz, Parray, Aijaz, Zar Gul, Abdul Rehman, Philip, Anite, Vijayakumar, Suma, Merhi, Maysaloun, Hydrose, Shereena, Inchakalody, Varghese Philipose, Al-Abdulla, Rajaa, Abualainin, Wafa, Sirriya, Shaza Abu, Al-Bozom, Issam, Uddin, Shahab, Khan, Omar Muhammad, Mohamed Ibrahim, Mohamed Izham, Al Homsi, Ussama, Dermime, Said
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890181/ https://www.ncbi.nlm.nih.gov/pubmed/36741391 http://dx.doi.org/10.3389/fimmu.2022.1097117

Ejemplares similares

Serum immune mediators as novel predictors of response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients with high tissue-PD-L1 expression
por: Raza, Afsheen, et al.
Publicado: (2023)

Treatment with decitabine induces the expression of stemness markers, PD-L1 and NY-ESO-1 in colorectal cancer: potential for combined chemoimmunotherapy
por: Taib, Nassiba, et al.
Publicado: (2023)

Squamous Cell Carcinomas of the Head and Neck Cancer Response to Programmed Cell Death Protein-1 Targeting and Differential Expression of Immunological Markers: A Case Report
por: Merhi, Maysaloun, et al.
Publicado: (2018)

Dynamic liquid biopsy components as predictive and prognostic biomarkers in colorectal cancer
por: Raza, Afsheen, et al.
Publicado: (2022)

Persistent anti-NY-ESO-1-specific T cells and expression of differential biomarkers in a patient with metastatic gastric cancer benefiting from combined radioimmunotherapy treatment: a case report
por: Merhi, Maysaloun, et al.
Publicado: (2020)

Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy
por: Raza, Afsheen, et al.
Publicado: (2020)

Emerging dynamics pathways of response and resistance to PD-1 and CTLA-4 blockade: tackling uncertainty by confronting complexity
por: Relecom, Allan, et al.
Publicado: (2021)

Role of Epstein–Barr Virus in the Pathogenesis of Head and Neck Cancers and Its Potential as an Immunotherapeutic Target
por: Fernandes, Queenie, et al.
Publicado: (2018)

Leptomeningeal Metastatic L858R EGFR-mutant Lung Cancer: Prompt Response to Osimertinib in the Absence of T790M-mutation and Effective Subsequent Pulsed Erlotinib
por: Kanbour, Aladdin, et al.
Publicado: (2022)

Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines
por: Fernandes, Queenie, et al.
Publicado: (2022)

Persistence of spike-specific immune responses in BNT162b2-vaccinated donors and generation of rapid ex-vivo T cells expansion protocol for adoptive immunotherapy: A pilot study
por: Mestiri, Sarra, et al.
Publicado: (2023)

Editorial: Dynamic Biomarkers of Response to Anti-Immune Checkpoint Inhibitors in Cancer
por: Dermime, Said, et al.
Publicado: (2021)

PD−L1 immunostaining: what pathologists need to know
por: Akhtar, Mohammed, et al.
Publicado: (2021)

Correction: PD − L1 immunostaining: what pathologists need to know
por: Akhtar, Mohammed, et al.
Publicado: (2022)

CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances
por: Maalej, Karama Makni, et al.
Publicado: (2023)

Evaluation of cationic channel TRPV2 as a novel biomarker and therapeutic target in Leukemia-Implications concerning the resolution of pulmonary inflammation
por: Siveen, Kodappully S., et al.
Publicado: (2019)

Targeting of X-linked inhibitor of apoptosis protein and PI3-kinase/AKT signaling by embelin suppresses growth of leukemic cells
por: Prabhu, Kirti S., et al.
Publicado: (2017)

Successful rechallenge with cisplatin following cisplatin induced ischemic cerebrovascular accident in a patient with small cell lung cancer
por: Rashid, Farah, et al.
Publicado: (2022)

Seven novel glucose-6-phosphate dehydrogenase (G6PD) deficiency variants identified in the Qatari population
por: Malik, Shaza, et al.
Publicado: (2021)

FOXP3(+ )T(regs )and B7-H1(+)/PD-1(+ )T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy
por: Ghebeh, Hazem, et al.
Publicado: (2008)

Role of Non Receptor Tyrosine Kinases in Hematological Malignances and its Targeting by Natural Products
por: Siveen, Kodappully S., et al.
Publicado: (2018)

Effect of Primary Systemic Therapy on PD-1, PD-L1, and PD-L2 mRNA Expression in Advanced Breast Cancer
por: Karsono, Ramadhan, et al.
Publicado: (2021)

In vitro Interleukin-7 treatment partially rescues MAIT cell dysfunction caused by SARS-CoV-2 infection
por: Hubrack, Satanay, et al.
Publicado: (2021)

The effect of protein mutations on drug binding suggests ensuing personalised drug selection
por: Wan, Shunzhou, et al.
Publicado: (2021)

PD-1 Independent Role of PD-L1 in Triple-Negative Breast Cancer Progression
por: Alkaabi, Duaa, et al.
Publicado: (2023)

Guggulsterone Induces Apoptosis in Multiple Myeloma Cells by Targeting High Mobility Group Box 1 via Janus Activated Kinase/Signal Transducer and Activator of Transcription Pathway
por: Akhtar, Sabah, et al.
Publicado: (2022)

Curcumin Induces Apoptotic Cell Death via Inhibition of PI3-Kinase/AKT Pathway in B-Precursor Acute Lymphoblastic Leukemia
por: Kuttikrishnan, Shilpa, et al.
Publicado: (2019)

Attenuated Salmonella potentiate PD-L1 blockade immunotherapy in a preclinical model of colorectal cancer
por: Al-Saafeen, Besan H., et al.
Publicado: (2022)

Coexpression of PD-L1/PD-1 with CXCR3/CD36 and IL-19 Increase in Extranodal Lymphoma
por: Saber, Manal Mohamed
Publicado: (2023)

Editorial: Genomics, proteomics and immunological signatures as diagnostic, predictive, and prognostic biomarkers in head and neck cancers
por: Raza, Afsheen, et al.
Publicado: (2023)

Sanguinarine Induces Apoptosis Pathway in Multiple Myeloma Cell Lines via Inhibition of the JaK2/STAT3 Signaling
por: Akhtar, Sabah, et al.
Publicado: (2019)

Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies
por: Puccini, Alberto, et al.
Publicado: (2020)

G6PD deficiency in the COVID-19 pandemic: Ghost within Ghost
por: Al-Abdi, Sameer, et al.
Publicado: (2021)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Increased CD86 but Not CD80 and PD-L1 Expression on Liver CD68(+) Cells during Chronic HBV Infection
por: Said, Elias A., et al.
Publicado: (2016)

Crosstalk between HER2 and PD-1/PD-L1 in Breast Cancer: From Clinical Applications to Mathematical Models
por: Padmanabhan, Regina, et al.
Publicado: (2020)

Bedside formulation of a personalized multi-neoantigen vaccine against mammary carcinoma
por: Mohsen, Mona O, et al.
Publicado: (2022)

Network Meta-analysis Comparing Efficacy, Safety and Tolerability of Anti-PD-1/PD-L1 Antibodies in Solid Cancers
por: Al-Showbaki, Laith, et al.
Publicado: (2021)

Discovery and Supramolecular Interactions of Neutral Palladium‐Oxo Clusters Pd(16) and Pd(24)
por: Bhattacharya, Saurav, et al.
Publicado: (2020)

PD-L1(ATTAC) mice reveal the potential of depleting PD-L1 expressing cells in cancer therapy
por: Fueyo-Marcos, Elena, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_i3ndg85vc8ksk8an8beuoc4ev1